PMFA
CLDX icon

Plante Moran Financial Advisors’s Celldex Therapeutics CLDX Stock Holding History

Plante Moran Financial Advisors’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-1
Closed – – 895
2018
Q3 		$0 Hold
1
– – ﹤0.01% 769
2018
Q2 		$0 Buy
+1
New +$13 ﹤0.01% 839

Other funds holding CLDX

CAM
Cresset Asset Management Chicago, Illinois $23.1B AUM 27.04% 1-Year Est. Return
KE
KLP Enterprises Branford, Connecticut $1.97M AUM
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MG
Meditor Group Hamilton, Bermuda $48.1M AUM 38.67% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCMG
TSP Capital Management Group Summit, New Jersey $410M AUM 71.81% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Plante Moran Financial Advisors's CLDX Position: Q4 2018 in Review

Plante Moran Financial Advisors sold out of Celldex Therapeutics (CLDX) in Q4 2018, closing a stake of 1 share.

Plante Moran Financial Advisors first reported a position in CLDX in Q2 2018 and held it in 2 quarters. The position peaked at $0 in Q3 2018. 85 funds tracked by Wall St. Rank hold CLDX as of Q4 2018.

  • Plante Moran Financial Advisors reported no remaining Celldex Therapeutics position as of Q4 2018 after selling out during the quarter.
  • Plante Moran Financial Advisors sold 1 Celldex Therapeutics share in Q4 2018.
  • Plante Moran Financial Advisors first reported a position in Celldex Therapeutics in Q2 2018 and held it in 2 quarters.
  • Plante Moran Financial Advisors's Celldex Therapeutics position peaked at $0 in Q3 2018.
  • 85 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q4 2018.

Based on Plante Moran Financial Advisors's 13F filing for Q4 2018, filed 29 Jan 2019.